2023 World Conference on Lung Cancer (Posters)-EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China

EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted in China to evaluate the response to first-line therapies in patients with stage IV non-small cell lung cancer (NSCLC) with RET fusions. The study included 86 eligible patients from six cancer centers between May 2017 and October 2022. The patients were treated with RET tyrosine kinase inhibitors (RET-TKI), chemotherapy, or various combination therapies as their first-line treatment.<br /><br />The results showed that RET-TKI had the best progress-free survival (PFS) among the treatment options, with a median PFS of 16.92 months. Combination therapy had a median PFS of 8.7 months, and chemotherapy had the worst PFS with a median of 5.55 months. The objective response rate (ORR) was also highest in the RET-TKI group at 71.4%, compared to 17.8% for combination therapy and 6.7% for chemotherapy.<br /><br />For patients who couldn't afford RET-TKI treatment, combination therapy with bevacizumab (BC) or a combination of immune checkpoint inhibitor and bevacizumab (IBC) provided better PFS compared to chemotherapy. However, the group receiving the combination of immune checkpoint inhibitor and chemotherapy (IC) had comparable PFS to the chemotherapy group.<br /><br />Although there was not a significant difference in survival between the three combination therapy groups, the IBC group had a longer median PFS of 12.21 months compared to the BC group (8.74 months) and the IC group (7.89 months).<br /><br />The most common adverse events in patients receiving RET-TKI were pneumonia and an increase in transaminases, both of which were mild to moderate in severity. The IBC treatment had the highest incidence of hematological toxicity and vomiting.<br /><br />Based on these findings, the study concludes that RET-TKI is the best option for first-line therapy in patients with RET fusion-positive NSCLC. However, IBC may be a preferable option for patients who cannot afford RET-TKI, but further investigation is needed. Additionally, BC showed favorable survival compared to chemotherapy.

Asset Subtitle

aiqin Gao

Meta Tag

Speaker aiqin Gao

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

ret-TKI

chemotherapy

combination therapy

RET fusions

non-small cell lung cancer

progress-free survival

objective response rate

bevacizumab

immune checkpoint inhibitor

adverse events